jkb-122
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 1, 2014 (NCT02293941)
Timeline
Indications
Mechanism of action
- Toll-like receptor 4ANTAGONIST
TLR4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- jkb-122
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04371718 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2020 | TaiwanJ Pharmaceuticals Co., Ltd |
| NCT04255069 | Phase 3 | Jun 30, 2020 | TaiwanJ Pharmaceuticals Co., Ltd |
| NCT04313205 | Phase 1 | Apr 30, 2020 | TaiwanJ Pharmaceuticals Co., Ltd |
| NCT02556372 | Phase 2 | Feb 1, 2016 | TaiwanJ Pharmaceuticals Co., Ltd |
| NCT02293941 | Phase 2 | May 1, 2014 | TaiwanJ Pharmaceuticals Co., Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TaiwanJ Pharmaceuticals Co., Ltd | For profit | 5 | 5 | 3 | 2014 |
1 organizations
Page 1 / 1